In this formulation study, biocompatible non steroidal anti-inflammatory (NSAIDs)-loaded nanoparticles were designed as models to be further integrated in a prosthesis surface functionalization. A modified spontaneous emulsion-solvent diffusion methodology was used to produce drug-loaded PLGA nanoparticles without any purification or solvent evaporation requirements. Formulation parameters, such as lactide/glycolide ratio, polymer concentration, solvent/non solvent ratio and non solvent phase, as well as the non ionic tensioactive P188 co-precipitation composition were systematically explored. The optimized formulation (mean size: 145 nm, surface charge: -13 mV) was employed to encapsulate various amounts of NSAIDs in a simple and scalable manner. The drug release was characterized in vitro by a complete release for 48 h. These results encourage upcoming preliminary steps for in vivo experiments of prosthesis surface functionalization.
The application of polymer-based nanoparticles to exploit biocompatible and biodegradable polymers offers tremendous perspectives as therapeutic vehicles for numerous drugs discarded on the basis of their adverse effects. Indeed, their unique physicochemical properties allow improving drug delivery efficiency to the affected area, and sustaining pharmacological effects [1] . Among those drugs, non steroidal anti-inflammatory drugs (NSAIDs) are especially relevant to such a strategy considering the variety of inflammation pathologies. In particular, it is one of the naturally-occurring processes in joint or bone surgery, when a prosthesis is cemented into the operation site. Perioperative NSAIDs may then be prescribed to reduce the pain in both the short-and long-term surgical outcomes [2] or even to reduce the risk of postoperative ectopic bone formation [3, 4] . Nevertheless, the oral administration of NSAIDs is correlated with severe adverse gastrointestinal complications and excessive wound bleedings [5, 6] . Nanotechnology may confer capability for prolonged and effective delivery of drug as a part of prosthesis surface functionalization.
Such nanoobjects, facing a complex and sensitive biological system as the human body, should meet manifold and extremely challenging requirements, such as biocompatibility, biodegradability, and atoxicity [7] . Furthermore, the production process should be simple, near-net-shape, sterile and easily scalable for cost-effective industrial production.
Following these aforementioned requirements, we aimed at designing NSAIDs-loaded biodegradable nanoparticles to be further coated onto prosthesis surface, in order to allow the local and controlled release of the selected NSAIDs. Poly(lactitde-co-DOI:10.3786/nml.v2i4.p247-255
http://www.nmletters.org glycolide) (PLGA) has been extensively studied for drug delivery applications as nanoparticle matrix material because of its recognized biocompatibility and biodegradability [1] . Various methods have been designed to prepare PLGA nanospheres [1, 7] . Among them, the Spontaneous Emulsification-Solvent Diffusion (SESD) method is a choice methodology since it is simple, low-energetic and reproducible [8] . Nevertheless, it generally implicates at the best class-3 residual solvents (such as acetone), which involves an additional purification and quantification step. In this preliminary formulation study, we aimed at optimizing this single-step, ready-to-use methodology with the restrained use of completely pharmaceutically-accepted components. A bottom-up, step-by-step strategy was applied to produce NSAIDs-loaded poly-(lactide-co-glycolide) (PLGA)
nano-particles, with desirable NSAIDs payloads and release profile. In this respect, the process feasibility and pitfalls were explored through the systematic assessment of formulation parameters and physicochemical characterization.
Materials and methods

Materials
Poly(lactide-co-glycolide) (PLGA, 50:50, 65:35, 85:15 lactide / glycolide, molecular weights of 40-75,000, 40-75,000
and 50-75,000 Da, respectively, as provided by the manufacturer)
were purchased from Sigma Aldrich. Poloxamer 188 (P188, i.e.
Pluronic®F-68, polyethyleneglycol-co-polypropyleneglycol-copolyethyleneglycol), the water-miscible solvent glycofurol [9] (i.e. tetraglycol or tetrahydrofurfurylalcohol polyethylene glycol ether) and indomethacin (minimum 99% TLC) were also obtained from Sigma. Water was exclusively water for injections (Aqua B. Braun, Braun, Germany). Ibuprofen (Fagron, France) was of European Pharmacopeia grade.
Preparation of PLGA nanoparticles
PLGA nanoparticles were prepared using a modified spontaneous emulsification-solvent diffusion method derived from Niwa et al. [8] . Briefly, the specified mass of PLGA was dissolved in 5 mL glycofurol, in the presence of various amounts of NSAIDs. This organic phase was poured at a constant flow rate of 2 mlmin -1 to a hydrophilic phase (usually 75 ml) containing 0.001 % w/v poloxamer P188, magnetically stirred at 400 rpm. Nanoparticles were spontaneously formed upon solvent phase diffusing into the hydrophilic phase, resulting in a slight blue shade (Tyndall effect). For surface modification, various amounts of poloxamer 188 were dissolved into the organic phase at the same time with the polymer and the drug, adopted from the methodology developed by Csaba et al. [10] .
The rest of the experiments were conducted in a strictly similar way. 
Nanoparticle size and Zeta potential
Morphological studies
The shape and surface morphology of the PLGA nanoparticles were investigated by transmission electron microscopy (TEM, CM30, Philips, Limeil-Brevannes, France) at an accelerating voltage of 250 kV. In prior analysis, samples were negatively stained with 2% (w/v) uranyl acetate for 1 min.
They were also examined by atomic force microscopy (AFM, Nanoscope III, Veeco, Dourdan, France) in tapping mode (scan rate: 1 Hz) using a silicon nitride tip with a constant spring of 46
Nm -1 and a resonant frequency around 300 kHz. Samples were prepared by placing a drop of PLGA nanoparticle suspension on a freshly cleaved mica sheet and allowed to dry in the air.
Experiments were performed at room temperature. To obtain Fig.   1 (c), after isolating a single nanoparticle, the AFM tip was used to apply a force in the middle of the nanoparticle and then, an image was performed in tapping mode to lower the interaction between the tip and the nanoparticle. 
NSAIDs quantification
For drug loading measurement, NSAIDs-loaded nanoparticle suspensions were centrifuged at 23,000 rpm and the suspension supernatants were quantified by HPLC. HPLC analyses were carried out with a C18 column (250×4.6 mm×5 µm) mounted on a Dionex system composed of a P680 HPLC Pump, an ASI-100 Automated Sample Injector and a UVD340U
detector. For ibuprofen, the mobile phase consisted of a mixture of acetonitrile/water 60/40 containing 1% o-phosphoric acid.
The flow rate was 0.5 ml/min and peaks were detected as 222 nm. Values were reported as the mean ± sd of four replicates.
Results and discussion
Prior examining and discussing the outcomes of various factors on the nanoparticle formation, it is important to state that spherical, individualized nanoparticles were obtained in a wide range of process conditions with fabrication yields over 90%
( Fig. 1) . TEM photographs showed a well-defined spherical particle shape, without noticeable aggregation ( Fig. 1(a) ). AFM images showed smooth nanoparticle surface ( Fig. 1(b) ). AFM also enabled us to precise the core-shell structure of the nanoparticles, as demonstrated by the possibility for the AFM tip to depress them upon contact ( Fig. 1(c) ). Nevertheless, it was not possible, with the use of present equipment, to quantify these phenomena.
Influence of process parameters on the nanoparticle characteristics
For efficient drug delivery, it is necessary that nanoparticle mean sizes and population polydispersity indexes should be kept as low as possible. desirable for the considered therapeutic application, which can be reached through monodisperse size populations [12] .
Preliminary studies on nanoparticle formation revealed that, to reach this goal, the critical factors during processing were lactide-to-glycolide ratio and polymer concentration. Other factors with great impacts on the final results were also examined, such as solvent/non-solvent volume ratio and tensioactive co-precipitation. Herein, solvent and non solvent refer to the ability to solubilize the polymer, solvent being glycofurol and non solvent being water, more or less enriched with tensioactive molecules.
L/G ratio
The influence of the lactide-to-glycolide (L/G) ratio on particle size is summarized in Table 1 , for similar molecular weights and a fixed polymer concentration. A clear trend of increasing particle sizes (as well as polydispersity indexes, PdIs)
with increasing the L/G ratio was observed. This phenomenon was previously reported with many types of polyester dissolved in a large variety of solvents, in the solvent diffusion process [13, 14] . In fact, an increase of the L/G induces an increase of polymer hydrophobicity due to a higher lactide percentage. This would, in turn, result in increased polymer-polymer interactions, and consequently larger particles. Finally, a higher proportion of lactide units leads to a larger relative amount of crystalline micro-domains in its solid state [15] . When the polymer precipitates during desolvation, such lactide domains would present more difficulties to fold and re-arrange in dense spherical features, leading globally to bigger particles. For these reasons, PLGA 50:50 was selected as the most suitable polymer in this study.
Polymer concentration
As already described, polymer concentration in the solvent phase, and hence viscosity, greatly affects the observed sizes [16] [17] [18] . The mechanism of particle formation during spontaneous emulsification occurs according to "diffusionstranding" process, also known as the Marangoni effect [18] [19] [20] .
In this respect, the polymer concentration was varied in order to alter the inner solvent phase viscosity and, consequently the solvent diffusion rate into the non-solvent phase [17] . Contrary to what was generally observed [17] [18] [19] [20] [21] , a linear response between polymer concentration and hydrodynamic diameters was not observed in this study ( Fig. 2(a) ). On the opposite, there seemed to be a critical PLGA concentration (with our protocol 2 % w/v) above which the hydrodynamic diameters and PdIs were characterized by erratic values. This phenomenon was already observed in the case of nanoparticles produced by spraying PLGA-glycofurol solution into water [22] . It was as if the solvent molecules were being able to diffuse normally into the non-solvent phase until a critical polymer concentration was reached, which blocked the small solvent molecules into the folded polymer chains. This could demonstrate that the diffusion process is hampered by the affinity between solvent molecules and polymer chains, i.e. the balance between forces involved into polymer solvation and the ones involved into solvent diffusion, as stated by Choi et al. [23] . Further investigations were therefore conducted with a 1.5% PLGA concentration. Results are given as means ± sd, n = 3 to 9.
Solvent/Non-solvent phases (S/NS) ratio
The effect of varying the solvent (glycofurol)-to-non solvent (water) volume ratio (S/NS) during polymer precipitation was investigated, from 1 to 20 % (v/v) ( Fig. 2(b) ).
Overall, for a fixed 1.5% PLGA concentration, sizes decreased with decreasing the S/NS ratio, until a minimum was reached around 7%. In our system, phase transfer was not instantaneous since glycofurol was more viscous than water (8-18 vs 1 mPas at 20°C [9] ), resulting in a transient solvent concentration gradient into the non-solvent phase. Even if sink conditions were globally assumed, increasing the glycofurol/water ratio led to larger particles. This could be due to a locally solvent-saturated system at the interface, slowing down glycofurol diffusion [23] and therefore tending to favour nanodroplet collapses. This was partially visible through the evolution of zeta-potentials ( Fig.   2(b) ), which were far more negative for lower ratios than higher ones. This testifies for the presence of glycofurol molecules contributing to the double solvation layer when desolvation is not complete. Nevertheless, for a large scale of volume ratios, particles remained in the range of 200 nm or less. The presence of a plateau in the size evolution (for glycofurol/water ratio smaller than 7% v/v) reveals the existence of a maximal surface curvature, which could not be increased whatever the ratio.
Influence of tensioactive-polymer co-precipitation
The development of stealth nanoparticles as drug carriers, which could avoid or at least reduce the uptake by phagocytes and therefore an immunogenic response, has been thoroughly examined in the last decade [24, 25] . It is now well established that the adsorption of blood proteins (leading to surface opsonisation) on hydrophilic surfaces is greatly delayed compared to hydrophobic ones [25] . Surface adsorption or polymer grafting are general methods of choice to turn an hydrophobic surface (such as PLGA) into a more hydrophilic one, using either long hydrophilic polymer chains (like polysaccharides or PEG) or non-ionic surfactants (for example PVAL, poloxamers and poloxamines). In this prospect, the co-precipitation approach developed by Alonso and co-workers is particularly interesting. They initiated a technique in which either poloxamines (Tetronic® 904 and 908) or poloxamers (Pluronic® F68 and L121) were co-dissolved in the solvent phase and nanoprecipitated into an aqueous phase [26] . During precipitation, the tensioactive molecules placed at the solventnon solvent interface were trapped by physical entanglements with polymer chains. In this study, we applied this approach to DOI:10.3786/nml.v2i4.p247-255 http://www.nmletters.org would reduce the uptake of particles by the RES [24] , without affecting the drug entrapment efficiency [10] .
Sizes diminished with increasing P188 ratio in the glycofurol phase (Fig. 2(c) ). Indeed, the more P188 molecules at the nanoparticle surface, the higher the hydrodynamic radius would appear, according to the Stockes-Einstein equation. The presence of the P188 tensioactive molecules, displaying a higher affinity for water than for glycofurol, must contribute to stabilize the spontaneous oil-in-water emulsion, leading to smaller micelle-like structures. Then upon polymer desolvation, the resulting solid particles present a smaller hydrodynamic diameter.
This can happen until the limit is reached (Fig. 2(c) ), limit which is controlled by: 1-the presence of polymer chains inside the nanodroplets; 2-the maximal surface curvature observed for this system.
NSAIDs encapsulation
NSAIDs-loaded nanoparticles were prepared from the optimized formulation, with a PLGA 50:50 :P188 1:1 ratio and a S/NS volume ratio of 6.6%. In the absence of P188 in the S observed for 4 h (Fig. 3 ), corresponding to a large proportion of drug present at or near the nanoparticle surface (Fig. 4(a) and (b)). Indeed, in equivalent experimental conditions, the recovery of the same quantity of free ibuprofen dissolved in a blank NP suspension was completed in 2 h (data not shown), whereas only about 60% were released in the case of ibuprofen-loaded nanoparticles (Fig. 3) . The rest (about 20%) must be located near the surface and then be washed out, with the adsorbed / dispersed part, by the water flow penetrating the polymer network ( Fig.   4(b) ). It was followed by a much slower phase (Fig. 3) , due to the entrapment of the drug deeper into the PLGA/P188 matrix ( Several factors affect the shape of the release pattern [31, 32] . The drug release from PLGA particles may depend on three primary mechanisms, i.e. polymer swelling, drug diffusion through polymer network, and polymer degradation via hydrolysis [32] . For high molecular weight PLA and PLGA systems, the diffusion process is dominant and principally drives the initial burst release mechanisms [33] . The second phase is more generally attributed to uniform degradation and erosion of the particle wall, modulated through the solvent diffusion and subsequent enrichment of the external medium [34] . Surprisingly, the role of the nature and diffusion kinetics of the remaining solvent molecules inside the nanoparticles is scarcely discussed.
In the case of nanocapsules, this role cannot be neglected since it constitutes a major component of the diffusional system. Thus, the remaining glycofurol molecules must contribute to plasticize the polymer chains and to solubilize the drug, modulating the NSAID release. Furthermore, this phenomenon would be re-enforced by the presence of PEG segments (from co-precipitated P188 molecules) [33] , since the polymer network would be enlarged and facilitate drug diffusion to external medium. Nevertheless, the release pattern observed herein is comparable to what others reported about NSAIDs of the same chemical natures [35] [36] [37] . Indeed there seems to be a general finding that PLGA nanoparticles within the 200-nm range display a complete release less than 24 h when loaded with such chemicals [7] . For prosthesis surface coating, such a release pattern should be adequate since, occurring in a larger period than 24 h, it could advantageously replace an oral daily preventive cure.
Conclusion
The aim of the study was to design stealth NSAID-loaded polymeric nanoparticles according to a one-step nanoprecipitation process to be further coated onto prosthesis surface for drug controlled release. To our knowledge, the use of parenteral solvent glycofurol to produce PLGA-based drug delivery systems is scarce and mainly concerns with macro-or microscopic systems [38] [39] [40] [41] . Glycofurol-based nanoparticles have only been reported once before this work, by spraying PLGA solution into water, with a lesser success in terms of particle production, size and drug loading efficiency [22] .
In this work, the influence of various processing variables on particle characteristics was systematically assessed and the optimised formulation parameters were applied to a successful encapsulation of NSAIDs. 
